Peptide receptor radionuclide therapy for neuroendocrine tumours: standardized and randomized, or personalized?

被引：20

作者：

Hofman, Michael S. ^{[1
,2
]}

Hicks, Rodney J. ^{[1
,2
]}

机构：

[1] Peter MacCallum Canc Ctr, Ctr Canc Imaging, Melbourne, Vic 3002, Australia

[2] Univ Melbourne, Dept Med, Melbourne, Vic, Australia

来源：

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2014年 / 41卷 / 02期

关键词：

RADIOLABELED SOMATOSTATIN ANALOG; PHASE-II; LU-177-OCTREOTATE; CHEMOTHERAPY; CAPECITABINE; CARCINOMAS; SURVIVAL; TOXICITY;

D O I：

10.1007/s00259-013-2621-6

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

引用

页码：211 / 213

页数：3

共 20 条

[1]

[Anonymous], 2009, OXF CTR EV BAS MED L

[2] The tumour sink effect on the biodistribution of 68Ga-DOTA-octreotate: implications for peptide receptor radionuclide therapy [J].

Beauregard, Jean-Mathieu ;

Hofman, Michael S. ;

Kong, Grace ;

Hicks, Rodney J. .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 (01) :50-56

[3] Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte Oncology Network [J].

Brizzi, Maria P. ;

Berruti, Alfredo ;

Ferrero, Anna ;

Milanesi, Enrica ;

Volante, Marco ;

Castiglione, Federico ;

Birocco, Nadia ;

Bombaci, Sebastiano ;

Perroni, Davide ;

Ferretti, Benedetta ;

Alabiso, Oscar ;

Ciuffreda, Libero ;

Bertetto, Oscar ;

Papotti, Mauro ;

Dogliotti, Luigi .

BMC CANCER, 2009, 9 :388

[4] Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours [J].

Claringbold, Phillip G. ;

Brayshaw, Paul A. ;

Price, Richard A. ;

Turner, J. Harvey .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 (02) :302-311

[5] Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study [J].

Cwikla, J. B. ;

Sankowski, A. ;

Seklecka, N. ;

Buscombe, J. R. ;

Nasierowska-Guttmejer, A. ;

Jeziorski, K. G. ;

Mikolajczak, R. ;

Pawlak, D. ;

Stepien, K. ;

Walecki, J. .

ANNALS OF ONCOLOGY, 2010, 21 (04) :787-794

[6] Long-Term Survival, Toxicity Profile, and role of F-18 FDG PET/CT scan in Patients with Progressive Neuroendocrine Tumors Following Peptide Receptor Radionuclide Therapy with High Activity In-111 Pentetreotide [J].

Delpassand, Ebrahim S. ;

Samarghandi, Amin ;

Mourtada, Jennifer Sims ;

Zamanian, Sara ;

Espenan, Gregory D. ;

Sharif, Roozbeh ;

MacKenzie, Shawn ;

Kosari, Kambiz ;

Barakat, Omar ;

Naqvi, Shagufta ;

Seng, John E. ;

Anthony, Lowell .

THERANOSTICS, 2012, 2 (05) :472-480

[7]

Hicks R J, 2010, Cancer Imaging, V10 Spec no A, pS83, DOI 10.1102/1470-7330.2010.9007

[8]

Hofman MS, 2012, DISCOV MED, V14, P71

[9]

Horsch Dieter, 2013, Recent Results Cancer Res, V194, P457, DOI 10.1007/978-3-642-27994-2_25

[10] 177Lu-octreotate, alone or with radiosensitising chemotherapy, is safe in neuroendocrine tumour patients previously treated with high-activity 111In-octreotide [J].

Hubble, Daniel ;

Kong, Grace ;

Michael, Michael ;

Johnson, Val ;

Ramdave, Shakher ;

Hicks, Rodney John .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2010, 37 (10) :1869-1875

← 1 2 →